A deliberate strategic shift away from advertising compounded GLP-1 products toward offering FDA-approved branded alternatives, including Novo Nordisk's Wegovy and Ozempic, in both injectable and oral forms.

Expected impact: Broadens consumer reach, eliminates litigation risks with major pharmaceutical manufacturers, and establishes Hims & Hers as an official participant in the mainstream healthcare ecosystem.

Expanding the company's digital health platform globally through strategic cross-border acquisitions, establishing localized operations with native-language healthcare providers.

Expected impact: Positions the company to scale to over $1 billion in international annual revenue within the next three years, serving major markets across the US, UK, Europe, Australia, Canada, and Japan.

Acquisition and development of a California-based peptide manufacturing facility to secure domestic supply chain durability and research future wellness offerings.

Expected impact: Provides greater control over product cost, quality, and availability, while positioning the company to launch personalized peptide treatments targeting preventive health and metabolic optimization.

Integrating virtually painless, micro-needle capillary blood sampling technology into the Hims & Hers platform to offer convenient, at-home routine diagnostics.

Expected impact: Enables the company to offer pain-free blood collection (TAP and HALO technologies) to support personalized treatment plans across cardiovascular, metabolic, and hormonal health.